Diabetes & EndocrinologyendocrinologyHypothyroidism
Phase 2 Study of XP-8121: Once-Weekly Subcutaneous Levothyroxine for Adult Hypothyroidism
By MedXY|Jun 5, 2026
A Phase 2 trial found that once-weekly subcutaneous levothyroxine (XP-8121) was generally well tolerated and suggested a dose conversion of about four times the daily oral dose for adults with hypothyroidism.